New Risk • Jul 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.22m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (70% average daily change). Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.22m market cap). Announcement • Jul 20
Regentis Biomaterials Ltd Receives Japanese Patent Allowance for GelrinC Manufacturing Technology Regentis Biomaterials Ltd. announced that the Japan Patent Office has issued a Notice of Allowance for the Company's patent application titled "Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof" for its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC, the Company's regenerative treatment for articular cartilage injuries. The allowance further strengthens Regentis' expanding global intellectual property portfolio supporting GelrinC in the treatment of painful and debilitating injuries to focal articular knee cartilage. This comes as the Company advances commercialization activities in Europe, has surpassed 50% enrollment in its pivotal U.S. trial, and is evaluating opportunities to expand into additional international markets. The allowed patent covers proprietary protein-polymer conjugate compositions and manufacturing methods designed to eliminate the use of organic solvents while enabling stable, ready-to-use liquid formulations. The technology offers important manufacturing advantages, including improved process efficiency - 5x increase in yield, enhanced environmental profile, simplified production, and additional scalability for commercial manufacturing. The patent complements Regentis' growing worldwide intellectual property portfolio protecting GelrinC across product composition, manufacturing methods and therapeutic applications. Japan represents one of the world's largest and fastest-growing markets for cartilage repair technologies. Independent market research estimates the Japanese cartilage repair market will grow to nearly $289 million by 2030, driven by an aging population and increasing demand for joint-preserving therapies. Published research estimates that approximately 25 million people in Japan over the age of 40 have radiographic knee osteoarthritis, including roughly 8 million patients with symptomatic disease, underscoring the growing need for innovative cartilage repair treatments. Regentis' lead product, GelrinC, is a cell-free, off-the-shelf hydrogel implant having synchronized erosion and resorption for the treatment of painful and debilitating injuries to focal articular knee cartilage. As an innovative regenerative medical product, GelrinC offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 5 years, based on clinical study results to date. No effective off-the-shelf, ready to use treatment for focal knee cartilage defects is currently available on the market. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment. Announcement • Jun 26
Regentis Biomaterials Ltd. announced that it has received $6.5 million in funding On June 25, 2026, Regentis Biomaterials Ltd. closed the transaction. The Placement Agent also received a $180,000 accountable expense reimbursement, a non-accountable expense allowance of $65,000 and 92,857 unregistered warrants to purchase ordinary shares. The transaction included participation from 22 investors. Announcement • Jun 19
Regentis Biomaterials Ltd. announced that it expects to receive $6.5 million in funding Regentis Biomaterials Ltd. entered into definitive securities purchase agreements with certain accredited and institutional investors for issuance of 1,844,543 common shares at a price of $3.50 per share for gross proceeds of $6,455,900.50; and 12,600 pre-funded warrants at a price of $3.4999 per pre-funded warrant for gross proceeds of $44,098.74; for aggregate gross proceeds of $6,499,999.24 on June 17, 2026. The company will also issue ordinary warrants to purchase up to 1,857,143 ordinary shares. The pre-funded warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable upon issuance and will not expire until exercised in full. The ordinary warrants have an exercise price of $4.20 per ordinary share, are immediately exercisable upon issuance and will expire on the five-year anniversary from the date of issuance. The offering is expected to close on or about June 23, 2026. The ordinary shares, the warrants and the ordinary shares issuable upon exercise of the warrants were offered and sold pursuant to an exemption from the registration requirements of the securities act of 1933, as amended, under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D promulgated thereunder. Announcement • Jun 15
Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million. Regentis Biomaterials Ltd. has withdrawn its Follow-on Equity Offering in the amount of $10.000002 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,333,334
Price\Range: $3
Discount Per Security: $0.21 Announcement • Jun 09
Regentis Biomaterials Ltd. Commences European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate Regentis Biomaterials Ltd. announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC in Europe, where it has CE Mark approval. The hands-on training program is designed to train orthopedic surgeons in the use of GelrinC, providing practical experience with the implantation procedure and supporting physician readiness ahead of market launch. The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital. Additional sessions are planned in other European markets. GelrinC is a cell-free implant for the treatment of knee cartilage lesions. The procedure utilizes a ready-to-use implant and a straightforward single-step implantation process, which takes approximately 10 minutes, and fits into the surgeon's workflow. Regentis is establishing a network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC. These centers are intended to serve as clinical hubs where experienced orthopedic surgeons will help train and support other physicians across Europe as the technology is introduced into clinical practice. Regentis is targeting an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus standard of care microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration study, which has completed over 50% enrollment. Announcement • May 29
Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026 Regentis Biomaterials Ltd., Annual General Meeting, Jul 02, 2026. Location: apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal, tel aviv, Israel New Risk • May 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$10.00m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$10.00m market cap). Announcement • May 03
Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million. Regentis Biomaterials Ltd. has filed a Follow-on Equity Offering in the amount of $10.000002 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,333,334
Price\Range: $3
Discount Per Security: $0.21 New Risk • Feb 26
New major risk - Revenue and earnings growth Earnings have declined by 5.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$20.7m market cap). Announcement • Jan 21
Regentis Biomaterials Ltd. Announces New Long-Term Imaging Data from Its Successfully Completed European Clinical Trial of GelrinC Regentis Biomaterials Ltd. announced new long-term imaging data from its successfully completed European clinical trial of GelrinC, demonstrating that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage. The analysis was conducted by Prof. Siegfried Trattnig of Vienna University and his colleagues, global leaders in cartilage MRI imaging, using validated methodologies accepted by both U.S. FDA and Europe's EMA regulators, further strengthening the translational and regulatory relevance of the findings. As an innovative regenerative medical product, GelrinC offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment. Announcement • Dec 04
Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million. Regentis Biomaterials Ltd. has completed an IPO in the amount of $10 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,250,000
Price\Range: $8
Discount Per Security: $0.56
Transaction Features: Sponsor Backed Offering New Risk • Nov 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$1.78m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$987k free cash flow). Shares are highly illiquid. Negative equity (-US$9.2m). Revenue is less than US$1m. Market cap is less than US$10m (US$1.78m market cap). Board Change • Sep 11
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Keith Valentine was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.